Result or no result has in fact come up top result. As far as I can determine, refer comments by the CEO in the 2 March announcement, the second half 2019 study has been rescued after identifying technical issues and running new samples. The change in outcome in the IPF mouse model is highly encouraging;
AD-214 - statistically significant reduction using Ashcroft score
Pirfenidone and Nintedanib - no statistically significant reduction in Ashcroft score
Undoubtedly, news has not only been communicated to shareholders but also potential licencing partners. The Investor Briefing sets the strategic case going forward "Ablynx sets the activity benchmark to be on track for $billion exit, AdAlta ready to accelerate".
1AD Price at posting:
8.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)